Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..

• ACT100 Injection (Drug): a single 5-mg subcutaneous injection
• Placebo for ACT100 (Drug): a single 5-mg subcutaneous injection
• ACT100 Injection (Drug): a single 25-mg subcutaneous injection
• Placebo for ACT100 (Drug): a single 25-mg subcutaneous injection
• ACT100 Injection (Drug): a single 100-mg subcutaneous injection
• Placebo for ACT100 (Drug): a single 100-mg subcutaneous injection
• ACT100 Injection (Drug): a single 300-mg subcutaneous injection
• Placebo for ACT100 (Drug): a single 300-mg subcutaneous injection
• ACT100 Injection (Drug): a single 600-mg subcutaneous injection
• Placebo for ACT100 (Drug): a single 600-mg subcutaneous injection
• ACT100 Injection (Drug): a single 800-mg subcutaneous injection
• Placebo for ACT100 (Drug): a single 800-mg subcutaneous injection

Primary outcomes

• Adverse Event(AE) [Day 1-84]
• Serious Adverse Event [Day 1-84]
• blood pressure [Day 1-84]
• pulse [Day 1-84]
• respiration [Day 1-84]
• body temperature [Day 1-84]
• Number of Participants with Abnormal Physical examination parameters [Day 1-84]
• Number of Participants with Abnormal Laboratory Parameters Findings [Day 1-84]
• Number of Participants with 12-Lead Electrocardiogram Findings [Day 1-84]

Secondary outcomes

• Area Under the plasma concentration-time Curve from time zero to the last measurable concentration(AUC₀-t) [Day 1-4,7,14,21,28,42,56,70,84]
• Area Under the plasma concentration-time Curve from time zero extrapolated to infinity(AUC₀-∞) [Day 1-4,7,14,21,28,42,56,70,84]
• Maximum observed plasma concentration(Cmax) [Day 1-4,7,14,21,28,42,56,70,84]
• Time to reach the maximum observed plasma concentration(Tmax) [Day 1-4,7,14,21,28,42,56,70,84]
• Terminal elimination half-life(t1/2) [Day 1-4,7,14,21,28,42,56,70,84]
• Apparent clearance (CL/F) [Day 1-4,7,14,21,28,42,56,70,84]
• Apparent volume of distribution(Vd/F) [Day 1-4,7,14,21,28,42,56,70,84]
• Levels of BDCA2 on the surface of plasmacytoid dendritic cells (pDCs) [Day 1-3,7,14,28,42,56,70,84]
• Peripheral blood pDC levels [Day 1-3,7,14,28,42,56,70,84]
• Anti-drug antibodies (ADA). [Day 1,28,56,84]
• Neutralizing antibodies (NAb) [Day 1,28,56,84]

Sex: All, ages: 18 Years to 55 Years, accepts healthy volunteers

Inclusion Criteria:

1. Participants must voluntarily participate and sign the informed consent form after being informed of the entire trial process and the potential adverse reactions of the investigational product.
2. Healthy male and female participants aged between 18 and 55 years (inclusive) at the time of signing the informed consent form.
3. Body mass index (BMI) at screening: 18.5 kg/m\^2 ≤ BMI < 28 kg/m\^2; body weight ≥ 50 kg (for males) / ≥ 45 kg (for females).
4. At screening, physical examination, vital signs, laboratory tests, electrocardiogram (ECG), etc., are all normal or show abnormalities judged by the investigator as having no clinical significance.
5. Females of childbearing potential and males must agree to use highly effective contraceptive methods (e.g., intrauterine device, condom) from screening until 3 months after administration of the investigational product and have no plan for sperm or egg donation.

Exclusion Criteria:

1. History of treatment with any drug targeting the same molecule (BDCA2) as the investigational product.
2. A 12-lead electrocardiogram (ECG) at screening showing abnormalities considered clinically significant by the investigator (e.g., QTcF > 450 ms for males or > 470 ms for females).
3. History of severe diseases of major organ systems, including but not limited to neurological, cardiovascular, hematological, autoimmune, renal, hepatic, gastrointestinal, pulmonary, endocrine, metabolic, or psychiatric disorders.
4. Presence of severe bacterial or viral infection (e.g., pneumonia, sepsis, herpes zoster), or fungal/parasitic infection within 2 months prior to screening; or any symptoms of active or suspected infection within 1 week prior to dosing.
5. Chronic infectious diseases such as chronic hepatitis B or C, AIDS, tuberculosis, etc. Exclusion applies if any of the following tests are positive at screening: Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), Hepatitis C antibody (HCVAb), Treponema pallidum antibody, Human Immunodeficiency Virus antibody (HIVAb); or if there is evidence of active or latent Mycobacterium tuberculosis infection at screening.
6. History of primary immunodeficiency, splenectomy, or any other underlying condition deemed by the investigator to confer a high risk of severe infection.
7. History of severe food or drug allergy, or known allergy to monoclonal antibodies.
8. Vaccination with a live attenuated vaccine within 1 month prior to screening, or any other vaccination within half a month prior to screening, or plans to receive any vaccine during the study period.
9. Use of any prescription drugs, over-the-counter medications (including Chinese herbal medicines, health supplements, etc.) within 14 days prior to the first dose of the investigational product, unless deemed by both the investigator and sponsor to have no impact on the study.
10. History of drug abuse, illicit drug use, or alcohol abuse (history of drug abuse or illicit drug use within the past 5 years; or habitual alcohol intake exceeding 14 units per week within 3 months prior to screening: 1 unit ≈ 285 mL beer, or 25 mL spirits, or 100 mL wine). Participants with a positive alcohol breath test or positive urine drug abuse screening at screening will be excluded.
11. Heavy smoking (averaging >5 cigarettes per day) within 3 months prior to screening, or unwillingness to refrain from smoking during the study period.
12. Donation or loss of >400 mL of blood within 3 months prior to screening, or >200 mL within 1 month prior to screening; or receipt of blood transfusion or blood products within 3 months prior to screening.
13. Participation in another clinical trial involving an investigational drug/therapy within 1 month prior to screening, or within 5 half-lives (based on the known half-life of the prior investigational product, the Investigator's Brochure, or the informed consent form, whichever specifies the longer period).
14. History of blood/needle phobia or intolerance to venipuncture, or abnormalities at the potential injection site deemed by the investigator to be unsuitable for subcutaneous administration.
15. Females who are pregnant or lactating.
16. Any other condition that, in the judgment of the investigator, makes the participant unsuitable for participation in this study.

• Xiaohong Han, Principal investigator, Peking Union Medical College Hospital